C9orf78

Across TCGA pan-cancer cohorts, C9orf78 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated C9orf78 data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher C9orf78 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C9orf78 expression acts as an unfavorable survival marker.

STAD, SKCM, and SARC are the cancer types where C9orf78 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.250	0.729	.028	12	view →
SKCM	OS	Median	All	0.179	0.781	<.001	12	view →
SARC	DFS	Median	All	0.079	0.611	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CESC	OS	Median	All	0.553	0.876	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

C9orf78–STAD (OS)

Open the STAD breakdown →